A phase 1/2 open-label study of safety and antitumor...

European Urology Supplements 2016 / 12 Vol. 15; Iss. 13

A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone

Attard, G., Montgomery, R., Vaishampayan, U., Gordon, M., Smith, D., Antonarakis, E., Rudsinski, E., Perabo, F., Chi, K., Fizazi, K.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
15
Language:
english
Journal:
European Urology Supplements
DOI:
10.1016/s1569-9056(16)30439-0
Date:
December, 2016
File:
PDF, 216 KB
english, 2016
Conversion to is in progress
Conversion to is failed